← Back to Screener
Galapagos NV (GLPG)
Price$29.28
Favorite Metrics
Price vs S&P 500 (26W)-25.19%
Price vs S&P 500 (4W)-21.47%
Market Capitalization$1.92B
P/E Ratio (Annual)5.07x
All Metrics
Book Value / Share (Quarterly)$57.84
P/TBV (Annual)0.57x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)26.30%
Cash Flow / Share (Quarterly)$-4.85
Price vs S&P 500 (YTD)-15.15%
Gross Margin (TTM)98.19%
Net Profit Margin (TTM)50.24%
EPS (TTM)$5.73
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$5.73
Revenue Growth (5Y)15.97%
EPS (Annual)$5.74
ROI (Annual)9.90%
Gross Margin (Annual)97.33%
Net Profit Margin (5Y Avg)13.47%
Cash / Share (Quarterly)$53.59
P/E Basic Excl Extra (TTM)5.07x
Revenue Growth QoQ (YoY)184.69%
P/E Normalized (Annual)5.07x
ROA (Last FY)9.42%
Revenue Growth TTM (YoY)95.25%
EBITD / Share (TTM)$6.93
ROE (5Y Avg)1.50%
Operating Margin (TTM)52.01%
Cash Flow / Share (Annual)$-4.85
P/B Ratio0.50x
P/B Ratio (Quarterly)0.57x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)1.49x
Net Interest Coverage (TTM)-1.68x
ROA (TTM)8.70%
EPS Growth QoQ (YoY)3033.03%
EV / EBITDA (TTM)3.99x
EPS Incl Extra (Annual)$5.74
Current Ratio (Annual)20.15x
Quick Ratio (Quarterly)20.00x
3-Month Avg Trading Volume0.08M
52-Week Price Return9.97%
P/E Incl Extra (TTM)5.07x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$57.83
P/S Ratio (Annual)1.46x
Asset Turnover (Annual)0.33x
52-Week High$32.74
Operating Margin (5Y Avg)-23.65%
EPS Excl Extra (Annual)$5.74
CapEx CAGR (5Y)-31.41%
Tangible BV CAGR (5Y)4.44%
26-Week Price Return-16.44%
Quick Ratio (Annual)20.00x
13-Week Price Return-15.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.15x
Enterprise Value$1,821.888
Revenue / Share Growth (5Y)15.68%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)3.76%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)0.81x
Pretax Margin (Annual)27.05%
Cash / Share (Annual)$53.59
3-Month Return Std Dev28.78%
Gross Margin (5Y Avg)89.02%
Net Income / Employee (TTM)$1
ROE (Last FY)9.92%
Net Interest Coverage (Annual)-1.20x
EPS Basic Excl Extra (Annual)$5.74
Receivables Turnover (TTM)30.54x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$5.73
Receivables Turnover (Annual)50.25x
ROI (TTM)11.55%
P/S Ratio (TTM)1.56x
Pretax Margin (5Y Avg)-1.53%
Revenue / Share (Annual)$19.88
Tangible BV / Share (Annual)$57.83
Price vs S&P 500 (52W)-25.12%
P/E Ratio (TTM)5.07x
EPS Growth TTM (YoY)331.50%
Year-to-Date Return-11.79%
5-Day Price Return2.92%
EPS Normalized (Annual)$5.74
ROA (5Y Avg)1.90%
Net Profit Margin (Annual)28.85%
Month-to-Date Return-5.65%
Cash Flow / Share (TTM)$-3.38
EBITD / Share (Annual)$6.26
Operating Margin (Annual)26.53%
LT Debt / Equity (Annual)0.58x
ROI (5Y Avg)1.51%
P/E Excl Extra (TTM)5.07x
LT Debt / Equity (Quarterly)0.32x
EPS Basic Excl Extra (TTM)$5.73
P/TBV (Quarterly)0.57x
P/B Ratio (Annual)0.57x
Inventory Turnover (TTM)0.81x
Pretax Margin (TTM)50.17%
Book Value / Share (Annual)$57.84
Price vs S&P 500 (13W)-18.68%
Beta0.79x
P/FCF (Annual)0.55x
Revenue / Share (TTM)$18.61
ROE (TTM)11.59%
52-Week Low$22.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GLPGGalapagos NV | 1.56x | 95.25% | 98.19% | — | $29.28 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Galapagos NV is a fully integrated biotechnology company developing medicines for oncology and immunology, with operations in Europe and the United States. Its pipeline includes CAR-T cell therapies for blood cancers and a TYK2 inhibitor for autoimmune diseases currently in Phase 2 development. The company generates the majority of its revenue from the United States market.